FeesSafety
Pluang+

Safusidenib shows 81.5% clinical benefit in long-term study for IDH1-mutant glioma patients

Company Fundamentals
16 Nov 2026, 15:00 WIB
PRNewsWire
View Source
Bullish
Safusidenib shows 81.5% clinical benefit in long-term study for IDH1-mutant glioma patients

Nuvation Bio announced updated long-term data from its Phase 2 J201 study of safusidenib in patients with Grade 2 IDH1-mutant glioma, showing an 81.5% confirmed clinical benefit rate and durable tumor shrinkage over nearly 40 months. The drug demonstrated a manageable safety profile with mostly low-grade side effects and a median lesion reduction of 27.2%. These results support safusidenib as a promising treatment option that may delay more toxic therapies and provide sustained disease control. The company is advancing to a global Phase 3 SIGMA study to further evaluate safusidenib's efficacy and safety.

Nuvation Bio's stock is trading at USD 3.96 on Pluang, down 0.75% as of Nov 16, 2026 19:41 WIB. The company has a market cap of $1.41 billion with a typical hold time of 16 days on the platform.

More News (NUVB)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App